FHI Clinical announces intent to acquire South African-based Triclinium Clinical Development (TCD)

December 2, 2021

Acquisition allows FHI Clinical to expand its share of the infectious disease (ID) clinical development market and become dominant service provider in sub-Saharan Africa.

DURHAM, NORTH CAROLINA — FHI Clinical Inc. announces today its intent to acquire Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South African-based CRO and a subsidiary of EOH, one of the largest technology services companies in Africa. With this transaction, FHI Clinical will employ more than 425 global staff representing 12 countries.

Headquartered in Centurion (Gauteng), South Africa, TCD has significant access to the South African market—a competitive market with significant growth opportunity. South Africa accounts for most of the clinical trial activity in sub-Saharan Africa with the majority being infectious disease (ID) therapeutic studies. With approximately 285 employees already based in East and West Africa, FHI Clinical sees a unique opportunity to further expand its share of the ID market and become the dominant service provider in sub-Saharan Africa.

“TCD’s experience and credibility in the South African market, marked by long-term client relationships and follow-on business, is a fit for our strategic vision,” said Ted FitzGerald, FHI Clinical CEO. “In addition to therapeutic alignment as an infectious disease CRO, TCD also provides the opportunity to expand our organizational ability to conduct trials in low- and middle-income countries better positioning us to repeat that success anywhere in the world.”

Founded in 2000, TCD has been awarded contracts from both large pharma and smaller biotechs across a variety of therapeutic areas, including ID studies such as malaria and HIV, and has a long history and particular expertise in tuberculosis trials. Current studies in TCD’s portfolio include both innovative vaccines and treatments spanning all phases of clinical research from single-dose Phase I trials to large multi-site Phase 3 and Phase 4 trials.

“We knew FHI Clinical would be the best strategic fit for our organization as we have enjoyed a decade-long collaborative working relationship as preferred providers of the Global Health Clinical Consortium (GHCC),” commented Abraham Van Wyk, CEO, TCD. “We’re excited to bring our complementary expertise and enhanced presence of regional experts to help showcase South Africa as a clinical trial destination.”

About FHI Clinical

FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world. Benefitting from our 50+ year history of clinical research, our global team has worked on studies in more than 70 countries. As problem solvers, forward thinkers and on-the-ground members of those communities, we are dedicated to helping you find solutions to the research challenges that have kept life-saving therapies from at-risk populations. Visit fhiclinical.com or contact us at info@fhiclinical.com or 919.321.3321 to learn how we can put our diverse clinical and operational expertise to work for you.

About EOH

EOH is one of the largest technology services companies in Africa and has a wide range of solutions in Industry Consulting, IT Services, Software, Industrial Technologies and Business Process Outsourcing. The Group continues to be an undisputed market leader in its core ICT businesses, which operate principally under the iOCO brand name. The nature of this business is systemic to both the public and private sector and is an integral technology partner for a number of South Africa’s leading JSE-listed, blue-chip companies as well as key metros and government departments. Its other business, NEXTEC, collaborates with world-leading technology providers to design, implement and manage intelligent value-adding infrastructure and people solutions that make a positive and lasting impact. The Group’s more than 6000 employees deliver services to over 5,000 enterprise customers across all major industries throughout South Africa, Africa, Europe and the Middle East. As a proudly South African business, EOH is committed to sustainable transformation, making a positive, meaningful contribution to society, and is a Level 1 Broad-based Black Economic Empowerment (B-BBEE) contributor.

Press Contacts

Molly Thompson for FHI Clinical

Michael Rubenstein — Aprio
(+27) 82 903 7797

Zihle Nonganga
Head of EOH Investor Relations and Group Communications
(+27) 11 607 8100

news archive

Share this post